medigraphic.com

2000, Number 3

<< Back

Arch Cardiol Mex 2000; 70 (3)

Low plasma levels of high density lipoproteins in coronay artery disease

Pérez-Méndez O, Luc G, Posadas-Romero C

Language: Spanish
References: 62
Page: 312-321
PDF size: 285.16 Kb.


Text Extraction

No abstract


REFERENCES

  1. Gordon t, castelli wp, hjortland mc, dawber tr: High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62: 707-714.

  2. Miller gj, miller ne: Plasma high density lipoprotein concentration and development of ischaemic heart disease. Lancet 1975; 1: 16-19.

  3. Miller ne: Associations of high-density lipoprotein subclasses and apolipoproteins with ischaemic heart disease and coronary atherosclerosis. Am Heart J 1987; 113: 589-597.

  4. Parra hj, arvelier d, evans ae, cambou jp, amouyel p, bingham a, et al: A case-control study of lipoprotein particles in two populations at constraining risk for coronary heart disease. Arterioscler Thromb 1992; 12: 701-707.

  5. Phillips mc, rothblat gh: HDL and cholesterol efflux. Atherosclerosis 1997; 134: 114.

  6. Williams pt, vranizan km, austin ma, Krauss rm: Association of age, adiposity, alcohol intake, menstrual status and estrogen therapy with high density lipoprotein subclasses. Arterioscler Thromb 1993, 13: 1654-1661.

  7. Castro gr, fielding cj: Early incorporation of cell-derived cholesterol into pre-b-migrating high density lipoprotein pathway. Biochemistry 1988; 27: 25-29.

  8. Koizumi j, mabushi h, takeda r: Deficiency of serum cholestery lester transfer activity in patients with familial hyperalphalipoproteinaemia. Arteriosclerosis 1985; 58: 175-186.

  9. Abbey m, calvert gd: Effects of blocking plasma transfer protein activity in the rabbit. Biochim Biophys Acta 1989; 1003: 20-29.

  10. Tan kc, shiu sw, kung aw: Effect of thyroid dysfunction on high-density lipoprotein subfraction metabolism: roles of hepatic lipase and cholesteryl ester transfer protein. J Clin Endocrinol Metab 1998; 83: 2921-2924.

  11. Tan kc, shiu sw, kung aw: Plasma cholesteryl ester transfer protein activity in hyper and hypothyroidism. J Clin Endocrinol Metab 1998; 83: 140-143.

  12. Cushing sd, berliner ja, valente aj, territo mc, navab m, parhami f, et al: Minimally modified low density lipoprotein induces monocyte chemotactic protein (MCP-1) in human endotelial and smooth muscle cells. Proc Natl Acad Sci 1990; 87: 5134-5138.

  13. Seifert ps, kazatchine md: Generation of complement anaphylatoxins and C5b-9 by crystalline cholesterol oxidation derivatives depends on hydroxyl group number and position. Mol Immunol 1987; 24: 1303-1308.

  14. Torzewiski j, oldroyd r, lachman p, fitzimmons c, proudfoot d, bowyer d: Complement-induced release of lesion formation. Arterioscler Thromb Vasc Biol 1996; 16: 673-677.

  15. Watson ad, berliner ja, hama sy, La Du bn, faull kf, fogelman am, et al: Protective effect of high density lipoprotein associated paraoxonase. J Clin Invest 1995; 96: 2882-2891.

  16. Sanghera dk, saha n, aston ce, kamboh y: Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 1997; 17: 1067-1073.

  17. Aviram m, rosenblat m, bisgaier cl, newton rs, primo-parmo sl, la du b: Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. J Clin Invest 1998; 101: 1581-1590.

  18. Parthasarathy s, barnett j, fong lg: High density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990; 1044: 275-283.

  19. Abbot na, mackness mi, kumar s, boulton ajm, durrington pn: Serum paraoxonase activity, concentration and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995; 15: 812-818.

  20. Nevin dn, zambon a, furlong ce, richter rj, humbert r, hokanson je, et al: Paraoxonase genotypes, lipoprotein lipase activity, and HDL. Arterioscler Thromb Vasc Biol 1996; 16: 1243-1249.

  21. Shih dm, gu l, hama s, xia yr, navab m, fogelman am, lusis aj: Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest 1996; 97: 1630-1639.

  22. De Backer g, rosseneu m, deslypere tp: Discriminative value of lipids and apolipoproteins in coronary disease. Atherosclerosis 1982; 42: 197-203.

  23. Franzen j, fex g: Low serum lipoprotein A-I in acute myocardial infraction survivors with normal HDL cholesterol. Atherosclerosis 1986; 59: 37-42.

  24. Rubin em, krauss r, spangler e, verstuyft s, clift s: Inhibition of early atherogenesis in transgenic mice by human apolipoprotein A-I. Nature 1991; 353: 265-267.

  25. Hayec t. Oiknine j, danker g, brook jg, aviram m: HDL apolipoprotein A-I attenuates oxidative modification of low-density lipoprotein: studies in transgenic mice. Eur J Clin Chem Clin Biochem 1995; 33: 721-725.

  26. Li h, reddick rl, maeda n: Lack of apo A-I is not associated with increased susceptibility to atherosclerosis in mice. Arterioscler Thromb 1993; 13: 1814-1821.

  27. Huang y, eckardstein a, wu s, maeda n, assmann g: A plasma lipoprotein containing only apolipoprotein E and with mobility on electrophoresis releases cholesterol from cells. Proc Natl Acad Sci USA 1994; 91: 1834-1838.

  28. Stangl h, cao g, wyne kl, hobbs hh: Scavenger receptor, class B, type I-dependent stimulation of cholesterol esterification by high density lipoprotein, low density lipoproteins, and nonlipoprotein cholesterol. J Biol Chem 1998; 273: 31002-31008.

  29. Landschulz kt, pathak rk, rigotti a, krieger m, hobbs hh: Regulation of scavenger receptor, class B. type I, a high density lipoprotein receptor, in liver and steroidogenic tissues of the rat. J Clin Invest 1996; 98: 984-995.

  30. Rigotti a, edelman er, seifert p, iqbal sn, demattos rb, temel re, et al: Regulation by adrenocorticotropic hormone of the in vivo expression of scavenger receptor class B type I (SR-BI), a high density lipoprotein receptor, in steroidogenic cells of the murine adrenal gland. J Biol Chem 1996; 271: 33545-33549.

  31. Wang n, weng w, breslow jl, tall ar: Scavenger receptor BI (SR-BI) is up-regulate in adrenal gland in apolipoprotein A-I and hepatic lipase knock-out mice as a response to depletion of cholesterol stores. In vivo evidence that SR-BI is a functional high density lipoprotein receptor under feedback control. J Biol Chem 1996; 271: 21001-21004.

  32. Kwiterovich PO: The antiatherogenic role of high-density lipoprotein cholesterol. Am J Cardiol 1998; 82: 13Q-21Q.

  33. Ahumada am, jimenez vc, cardoso sg, sienra pj, zamora gj, posadas rc: Hypoalphalipoproteinemia and atherosclerosis. Genetic and biochemical profile of 10 families. Arch Inst Cardiol Méx 1989; 59: 9-18.

  34. Borecki ib, laskarzewski p, rao DC: Genetic factors influencing apolipoprotein AI and AII levels in a kindred with premature coronary heart disease. Genet Epidemiol 1988; 5: 393-406.

  35. Borecki ib, rao dc, third jl, laskarzewski pm, glueck cj: A major gene for primary hypoalphalipoproteinemia. Am J Hum Genet 1986; 38: 373-381.

  36. Byard pj, borecki ib, glueck cj, laskarzewski pm, third jl, rao dc: A genetic study of hypoalphalipoproteinemia. Genet Epidemiol 1984; 1: 43-51.

  37. Glueck cj, melser ma, borecki ib, third jl, rao dc, laskarzewski pm: Familial hypoalphalipoproteinemia. Adv Exp Med Biol 1986; 201: 83-92.

  38. Tall A: Plasma lipid transfer proteins. Annu Rev Biochem 1995; 64: 235-257.

  39. Jiang x-c, bruce c, mar j, lin m, ji y, francone ol, et al: Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Invest 1999; 103: 907-914.

  40. Johansson j, nilsson-ehle p, carlson la, hamsten a: The association of lipoprotein and hepatic lipase activities with high density lipoprotein subclass levels in men with myocardial infarction at young age. Atherosclerosis 1991; 86: 111-122.

  41. Serfaty-lacrosniere c, civeira f, lanzberg a, isaia P, berg j, janus ed, et al: Homozygous Tangier disease and cardiovascular disease. Atherosclerosis 1994; 107: 85-98.

  42. Norum ra, lakier jb, goldstein s, angel a, goldberg rb, block wd, et al: Familial deficiency of apolipoproteins AI and CIII and precocious coronary-artery disease. N Engl J Med 1982; 306: 1513-1519.

  43. Schaefer ej, ordovas jm, law sw, ghiselli g, kashyap ml, srivastava ls, et al: Familial apolipoprotein AI and CIII deficiency, variant II. J Lipid Res 1985; 26: 1089-1101.

  44. Franceschini g, sirtori cr, capurso a, weisgraber kh, mahley RW: A-I Milano Apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest 1980; 66: 892-900.

  45. Bruckert e, von eckardstein a, funke h, beucler i, wiebusch h, turpin g, et al: The replacement of arginine by cysteine at residue 151 in apo A-I produces a phenotype similar to that of apolipoprotein A-I Milano. Atherosclerosis 1997; 128: 121-128.

  46. Pérez-méndez o, castro g, fruchart jc, luc g: Kinetic and metabolic studies of apo A-I and apo A-II in an hypoalphalipoproteinemic patient. Eur J Neurology 1995; 2 (Suppl 1): 77.

  47. Elhalil l, majd z, bakir r, pérez-méndez o, castro g, poulain p, et al: Fish eye disease: Structural and in vivo metabolic abnormalities of high density lipoproteins. Metabolism 1997; 46: 474-483.

  48. Rader dj, gregg re, meng ms, schaefer jr, zech la, benson nm, et al: In vivo metabolism of a mutant apolipoprotein, apo A-I Iowa, associated with hypoalphalipoproteinemia and hereditary systemic amyloidosis. J Lipid Res 1992; 33: 755-763.

  49. Rader dj, ikewaki k, duverger n, feuerstein i, zech l, connor w, et al: Very low high-density lipoproteins without coronary atherosclerosis. Lancet 1993; 342:1455-1458.

  50. Roma p, gregg re, Meng ms, ronan r, zech la, franceschini g, et al: In vivo metabolism of a mutant form of apolipoprotein A-I Milano, associated with familial hypoalphalipoproteinemia. J Clin Invest 1993; 91: 1445-1452.

  51. Pérez-méndez o, bruckert e, franceschini g, duhal n, lacroix b, bonte jp, et al: Metabolism of apolipoproteins A-I and A-II in subjects carrying similar apo A-I mutations, apo A-I Milano and apo A-I Paris. Atherosclerosis 2000; 148: 317-325.

  52. Schaefer ej, blum cb, levy ri, jenkins ll, alaupovic p, foster dm, et al: Metabolism of high density apolipoproteins in Tangier disease. N Engl J Med 1978; 299: 905-910.

  53. Nichols wc, gregg re, brewer hb, benson MD: Characterization of the gene for familial amyloidotic polyneuropathy (FAP III/Iowa) and genotyping by allele-specific PCR. Am J Hum Genet 1989; 45 (suppl): A210.

  54. Nichols wc, gregg re, brewer hb jr, benson md: A mutation in apolipoprotein A-I in the Iowa type of familial amyloidotic polyneuropathy. Genomics 1990; 8: 318-323.

  55. Von eckardstein a, funke h, henke a, altland k, benninghoven a, assmann g, et al: Apolipoprotein A-I variants: naturally occurring substitutions of proline residues affect plasma concentration of apolipoprotein A-I. J Clin Invest 1989; 84: 1722-1730.

  56. Matsunaga t, hiasa y, yanagi h, maeda t, hattori n, yamakawa k, et al: Apolipoprotein A-I deficiency due to a codon 84 nonsense mutation of the apolipoprotein A-I gen. Proc Natl Acad Sci 1991; 88: 2793-2797.

  57. Funke h, von eckardstein a, pritchard ph, karas m, albers jj, Assmann G: A frameshift mutation in the human apolipoprotein A-I gene causes high density lipoprotein deficiency, partial lecithin: cholesterol-acyltransferase deficiency, and corneal opacities. J Clin Invest 1991; 87: 371-376.

  58. Rall sc jr, weisgraber kh, mahley rw, ogawa y, Fielding cj, utermann g, et al: Abnormal lecithin: cholesterol acyltransferase activation by a human apolipoprotein A-I variant in which a single lysine residue is deleted. J Biol Chem 1984; 259: 10063-10070.

  59. Miller m, aiello d, pritchard h, friel g, zeller k: Apolipoprotein A-I (Zavalla) (Leu159—>Pro): HDL cholesterol deficiency in a kindred associated with premature coronary artery disease. Arterioscler Thromb Vasc Biol 1998; 18: 1242-1247.

  60. Miettinen he, jauhiainen m, gylling h, ehnholm s, palomaki a, miettinen ta, et al: Apolipoprotein A-IFIN (Leu159—>Arg) mutation affects lecithin cholesterol acyltransferase activation and subclass distribution of HDL but not cholesterol efflux from fibroblasts. Arterioscler Thromb Vasc Biol 1997; 17: 3021-32.

  61. Strobl w, jabs h-u, hayde m, holzinger t, assmann g, widhalm k: Apolipoprotein A-I (glu198-to-lys): a mutant of the major apolipoprotein of hiph-density lipoproteins occurring in a family with dyslipoproteinemia. Pediatr Res 1988; 24: 222-228.

  62. Ng ds, leiter la, vezina c, connelly pw, hegele ra: Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein A-I deficiency in a family with analphalipoproteinemia. J Clin Invest 1994; 93: 223-229.




2020     |     www.medigraphic.com